Circulating Tumor DNA and Hepatocellular Carcinoma

Research output: Contribution to journalArticle

Abstract

There is a clear and unmet need for biomarkers in hepatocellular carcinoma (HCC). Circulating cell free deoxyribonucleic acid (cfDNA) is a fragmented DNA subtype, found in the blood circulation. Circulating tumor DNA (ctDNA) is the fraction of total cfDNA, which originates from the primary tumor or metastases in patients with cancer. Earlier studies reported that quantitative measurement cfDNA has diagnostic and prognostic role for HCC. More recently, improvement in next-generation sequencing technology and better understanding of genetic or epigenetic alteration of HCC have allowed comprehensive analysis of mutational and methylation landscape of ctDNA. Hotspot mutation panels and methylation panels have both shown promising performance. None of these tests have yet been validated in longitudinal cohorts for preclinical detection of HCC. In this article, the authors discuss the currently available ctDNA detection technologies, their diagnostic and prognostic performance in HCC, and future research directions.

Original languageEnglish (US)
Pages (from-to)452-462
Number of pages11
JournalSeminars in Liver Disease
Volume39
Issue number4
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hepatocellular Carcinoma
DNA
Neoplasms
Methylation
Technology
Blood Circulation
Epigenomics
Biomarkers
Neoplasm Metastasis
Mutation

Keywords

  • biomarkers
  • carcinoma
  • cell-free nucleic acids
  • cfDNA
  • circulating biomarker
  • ctDNA
  • hepatocellular cancer
  • liver cancer

ASJC Scopus subject areas

  • Hepatology

Cite this

Circulating Tumor DNA and Hepatocellular Carcinoma. / Yang, Ju Dong; Liu, Minetta C.; Kisiel, John B.

In: Seminars in Liver Disease, Vol. 39, No. 4, 01.01.2019, p. 452-462.

Research output: Contribution to journalArticle

@article{a9ad85ae4249475b949ffc693abc210a,
title = "Circulating Tumor DNA and Hepatocellular Carcinoma",
abstract = "There is a clear and unmet need for biomarkers in hepatocellular carcinoma (HCC). Circulating cell free deoxyribonucleic acid (cfDNA) is a fragmented DNA subtype, found in the blood circulation. Circulating tumor DNA (ctDNA) is the fraction of total cfDNA, which originates from the primary tumor or metastases in patients with cancer. Earlier studies reported that quantitative measurement cfDNA has diagnostic and prognostic role for HCC. More recently, improvement in next-generation sequencing technology and better understanding of genetic or epigenetic alteration of HCC have allowed comprehensive analysis of mutational and methylation landscape of ctDNA. Hotspot mutation panels and methylation panels have both shown promising performance. None of these tests have yet been validated in longitudinal cohorts for preclinical detection of HCC. In this article, the authors discuss the currently available ctDNA detection technologies, their diagnostic and prognostic performance in HCC, and future research directions.",
keywords = "biomarkers, carcinoma, cell-free nucleic acids, cfDNA, circulating biomarker, ctDNA, hepatocellular cancer, liver cancer",
author = "Yang, {Ju Dong} and Liu, {Minetta C.} and Kisiel, {John B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1055/s-0039-1688503",
language = "English (US)",
volume = "39",
pages = "452--462",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Circulating Tumor DNA and Hepatocellular Carcinoma

AU - Yang, Ju Dong

AU - Liu, Minetta C.

AU - Kisiel, John B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There is a clear and unmet need for biomarkers in hepatocellular carcinoma (HCC). Circulating cell free deoxyribonucleic acid (cfDNA) is a fragmented DNA subtype, found in the blood circulation. Circulating tumor DNA (ctDNA) is the fraction of total cfDNA, which originates from the primary tumor or metastases in patients with cancer. Earlier studies reported that quantitative measurement cfDNA has diagnostic and prognostic role for HCC. More recently, improvement in next-generation sequencing technology and better understanding of genetic or epigenetic alteration of HCC have allowed comprehensive analysis of mutational and methylation landscape of ctDNA. Hotspot mutation panels and methylation panels have both shown promising performance. None of these tests have yet been validated in longitudinal cohorts for preclinical detection of HCC. In this article, the authors discuss the currently available ctDNA detection technologies, their diagnostic and prognostic performance in HCC, and future research directions.

AB - There is a clear and unmet need for biomarkers in hepatocellular carcinoma (HCC). Circulating cell free deoxyribonucleic acid (cfDNA) is a fragmented DNA subtype, found in the blood circulation. Circulating tumor DNA (ctDNA) is the fraction of total cfDNA, which originates from the primary tumor or metastases in patients with cancer. Earlier studies reported that quantitative measurement cfDNA has diagnostic and prognostic role for HCC. More recently, improvement in next-generation sequencing technology and better understanding of genetic or epigenetic alteration of HCC have allowed comprehensive analysis of mutational and methylation landscape of ctDNA. Hotspot mutation panels and methylation panels have both shown promising performance. None of these tests have yet been validated in longitudinal cohorts for preclinical detection of HCC. In this article, the authors discuss the currently available ctDNA detection technologies, their diagnostic and prognostic performance in HCC, and future research directions.

KW - biomarkers

KW - carcinoma

KW - cell-free nucleic acids

KW - cfDNA

KW - circulating biomarker

KW - ctDNA

KW - hepatocellular cancer

KW - liver cancer

UR - http://www.scopus.com/inward/record.url?scp=85073581601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073581601&partnerID=8YFLogxK

U2 - 10.1055/s-0039-1688503

DO - 10.1055/s-0039-1688503

M3 - Article

C2 - 31226727

AN - SCOPUS:85073581601

VL - 39

SP - 452

EP - 462

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -